IDEMIA Announces a Global Partnership With Bosch Building Technologies to Tap the $1bn Biometric Access Control Market
IDEMIA, the leader of Augmented Identity announced today a global partnership with Bosch Building Technologies, a global leader in the security market, to tap the fast-growing biometric access control market. According to market analysts1, this market at $1bn in 2021, will grow to $1.4 by 2024, twice the growth of traditional access control systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005582/en/
(Photo: Business Wire)
This booming market comes from the fact that a growing number of companies understand that for their security, they cannot rely anymore only on simple ID badges, that can be cloned (for older technologies still used by 44% of companies2) or simply stolen. The consequence is that it is never possible to know with certainty who is entering the premises. Biometrics, based on personal, physiological, unforgeable characteristics, provide the highest degree of certainty that the person passing the door is a genuine authorized employee. Bosch Building Technologies offers a software solution that manages different Bosch security subsystems like access control, video surveillance, fire alarm, public address and intrusion systems on one single platform, the Bosch Building Integration System (BIS). This robust and reliable security and life safety system is proven by over 3000 installations integrating 10 million detectors worldwide.
In order to add a biometric layer to BIS, Bosch has selected IDEMIA’s terminals: IDEMIA is the market leader of biometrics for access control with more than 25 year’s experience in that domain, and hundreds of thousands of terminals successfully deployed for a great variety of industries, throughout the world.
Bosch will offer IDEMIA’s flagship contactless biometric terminals:
- MorphoWaveTM , the only terminal in the world capable of scanning and verifying 4 fingerprints in less than 1 second through a quick, simple and fully touchless wave movement of the hand,
- VisionPass the most advanced facial recognition terminal combining 2D, 3D and infrared cameras with IDEMIA’s leading facial algorithms.
Both terminals combine high biometric accuracy, speed and convenience with a fully touchless user experience. They operate efficiently with sanitary masks and are therefore well adapted for Covid-prevention policies. IDEMIA terminals are already integrated with the BIS platform and with most gates and turnstile vendors. This will greatly facilitate deployments in Bosch specific markets with a focus on commercial buildings, industrial and logistics sites, government premises and airports/seaports.
“Bosch stands for quality and reliability. We want to offer innovative and fascinating solutions, as our slogan 'invented for life' states. When our customers are going to deploy biometric terminals for their security, they will be installed for years so we want to offer them the best option”, explains Gregor Schlechtriem, Senior Vice President Bosch Building Technologies Business Unit Access & Intrusion. “Idemia is therefore for us the right partner because of their technology expertise and field-proven quality and performances”, Schlechtriem continues.
“We are delighted to start this global partnership with Bosch”, commented Yves Portalier, EVP Biometric Devices and Automotive at IDEMIA. “The combination of our biometric devices with the BIS platform will be a strong offering for companies looking for a high level of security and user convenience”.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1 In particular leading market analysis firm OMDIA
2 According to a ASIS International 2019 survey
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005582/en/
Contact information
Press contact
IDEMIA:
Hanna SEBBAH
idemia@havas.com
+33 (0) 6 63 73 30 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 14:00:00 EET | Press release
The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026. “Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intent
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 14:00:00 EET | Press release
AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb
MSCI Announces Baer Pettit to Retire as President17.11.2025 14:00:00 EET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s strategy and success,” said MSCI Chairman and CEO Henry Fernandez. “I would like to thank Bae
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 13:58:00 EET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
